APRE

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 13

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F21 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.

F20 · ownership.direct: The shares are held by VV V CAN.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 12

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,178

F19 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.

F20 · ownership.direct: The shares are held by VV V CAN.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 11

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F18 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.

F17 · ownership.direct: The shares are held by VV V.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 10

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,428

F16 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.

F17 · ownership.direct: The shares are held by VV V.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 9

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,374

F15 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC CAN without consideration to its partners.

F11 · ownership.direct: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 8

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,823

F14 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VOA without consideration to its partners.

F9 · ownership.direct: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 7

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,231

F13 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VAF V without consideration to its partners.

F7 · ownership.direct: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 6

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,437,132

F12 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC V without consideration to its partners.

F5 · ownership.direct: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

SEC source: 0001123292-20-000665 · edgar.xml · nonDerivative · entry 1

KDev Investments AB · CIK 0001789888 · 10% owner

Karolinska Development AB · CIK 0001789932 · 10% owner

KCIF Co-Investment Fund KB · CIK 0001789966 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,234,289

F1 · security: The amount of securities of Aprea Therapeutics, Inc. (the "Issuer") reported as beneficially owned includes shares held of record by: KDev Investments AB, Karolinska Development AB and KCIF Co-Investment Fund KB (collectively, the "Reporting Persons").

F2 · ownership.nature: Karolinska Development AB ("Karolinska") is the majority owner and co-manager of KDev Investments AB and a limited partner of KCIF Co-Investment Fund KB. Karolinska and each of the other Reporting Persons disclaim beneficial ownership of any shares of the Issuer's Common Stock owned of record by any of the other Reporting Persons except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that any such entity is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The address of each of (i) KDev Investments AB, (ii) Karolinska Development AB, and (iii) KCIF Co-Investment Fund KB is Tomtebodavagen 23A, SE 171 65 Solna, Sweden.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 5

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,263

F10 · kind: Represents a change in the form of ownership of VVC CAN by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.

F11 · ownership.direct: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 4

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,617

F8 · kind: Represents a change in the form of ownership of VOA by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.

F9 · ownership.direct: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 3

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,506

F6 · kind: Represents a change in the form of ownership of VAF V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.

F7 · ownership.direct: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 2

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,210,937

F4 · kind: Represents a change in the form of ownership of VVC V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.

F5 · ownership.direct: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

SEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 1

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant V Luxco S.a.r.l. ("Luxco") to its shareholders without consideration.

F2 · ownership.direct: These Shares are directly held by Versant VI Luxco S.a.r.l. ("Luxco").

F3 · ownership.direct: Luxco is majority owned by Versant Venture Capital V, L.P.("VVC V") and minority owned by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), Versant Affiliates Fund V, L.P. ("VAF V" and together with VVC V and VOA, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V, LLC ("VV V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which is the general partner of VVC CAN.

SEC source: 0001104659-20-038882 · a4.xml · derivative · entry 1

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,000

Underlying: Common Stock · 127,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-20-038875 · a4.xml · derivative · entry 1

Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-20-038881 · a4.xml · derivative · entry 1

Korbel Gregory Alan · CIK 0001789032 · VP of Business Dev't

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,800

Underlying: Common Stock · 12,800 shares

Expires 2030-03-24

F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-20-038879 · a4.xml · derivative · entry 1

Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,600

Underlying: Common Stock · 31,600 shares

Expires 2030-03-24

F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-20-038880 · a4.xml · derivative · entry 1

Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001140361-19-018091 · form4.xml · derivative · entry 5

Versant Vantage I, L.P. · CIK 0001765253 · 10% owner

Versant Vantage I GP, L.P. · CIK 0001777651 · 10% owner

Versant Vantage I GP-GP, LLC · CIK 0001777653 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 512,995 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.nature: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.nature: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018091 · form4.xml · derivative · entry 4

Versant Vantage I, L.P. · CIK 0001765253 · 10% owner

Versant Vantage I GP, L.P. · CIK 0001777651 · 10% owner

Versant Vantage I GP-GP, LLC · CIK 0001777653 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,993,658 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.nature: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.nature: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018091 · form4.xml · nonDerivative · entry 3

Versant Vantage I, L.P. · CIK 0001765253 · 10% owner

Versant Vantage I GP, L.P. · CIK 0001777651 · 10% owner

Versant Vantage I GP-GP, LLC · CIK 0001777653 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,333

F4 · ownership.direct: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018091 · form4.xml · nonDerivative · entry 2

Versant Vantage I, L.P. · CIK 0001765253 · 10% owner

Versant Vantage I GP, L.P. · CIK 0001777651 · 10% owner

Versant Vantage I GP-GP, LLC · CIK 0001777653 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,519,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.nature: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.nature: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.nature: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018091 · form4.xml · nonDerivative · entry 1

Versant Vantage I, L.P. · CIK 0001765253 · 10% owner

Versant Vantage I GP, L.P. · CIK 0001777651 · 10% owner

Versant Vantage I GP-GP, LLC · CIK 0001777653 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,006,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.nature: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.nature: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.nature: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018090 · form4.xml · derivative · entry 5

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 512,995 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018090 · form4.xml · derivative · entry 4

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,993,658 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018090 · form4.xml · nonDerivative · entry 3

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 333,333

F4 · ownership.direct: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

F4 · ownership.nature: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.nature: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018090 · form4.xml · nonDerivative · entry 2

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,519,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0001140361-19-018090 · form4.xml · nonDerivative · entry 1

Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,006,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

SEC source: 0000899243-19-025205 · doc4.xml · derivative · entry 5

HealthCap VII, L.P. · CIK 0001645161 · 10% owner

HealthCap VII GP S.A. · CIK 0001790047 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 427,496 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F1 · derivative.exercise_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F1 · derivative.expiration_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-19-025205 · doc4.xml · derivative · entry 4

HealthCap VII, L.P. · CIK 0001645161 · 10% owner

HealthCap VII GP S.A. · CIK 0001790047 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,661,382 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F1 · derivative.exercise_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F1 · derivative.expiration_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-19-025205 · doc4.xml · nonDerivative · entry 3

HealthCap VII, L.P. · CIK 0001645161 · 10% owner

HealthCap VII GP S.A. · CIK 0001790047 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,366,104

F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-19-025205 · doc4.xml · nonDerivative · entry 2

HealthCap VII, L.P. · CIK 0001645161 · 10% owner

HealthCap VII GP S.A. · CIK 0001790047 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,099,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-19-025205 · doc4.xml · nonDerivative · entry 1

HealthCap VII, L.P. · CIK 0001645161 · 10% owner

HealthCap VII GP S.A. · CIK 0001790047 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,671,941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001140361-19-018087 · form4.xml · derivative · entry 5

Christenson Johan · CIK 0001488771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 427,496 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

SEC source: 0001140361-19-018087 · form4.xml · derivative · entry 4

Christenson Johan · CIK 0001488771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,661,382 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

SEC source: 0001140361-19-018087 · form4.xml · nonDerivative · entry 3

Christenson Johan · CIK 0001488771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,366,104

F2 · ownership.direct: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

SEC source: 0001140361-19-018087 · form4.xml · nonDerivative · entry 2

Christenson Johan · CIK 0001488771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,099,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

SEC source: 0001140361-19-018087 · form4.xml · nonDerivative · entry 1

Christenson Johan · CIK 0001488771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,671,941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

F2 · ownership.nature: These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.

SEC source: 0001140361-19-018081 · form4.xml · nonDerivative · entry 1

Magni Guido · CIK 0001437150 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

SEC source: 0001140361-19-018079 · form4.xml · derivative · entry 2

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,407

Underlying: Common Stock · 18,407 shares

Expires 2029-10-02

F1 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001140361-19-018079 · form4.xml · nonDerivative · entry 1

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001140361-19-018070 · form4.xml · derivative · entry 9

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306,085

Underlying: Common Stock · 306,085 shares

Expires 2029-10-02

F2 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 7

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 5,000

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 6

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By adult child

Disclosed balance after: 1,000

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 5

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By adult child

Disclosed balance after: 1,000

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 4

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By adult child

Disclosed balance after: 1,000

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 3

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By adult child

Disclosed balance after: 1,000

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 2

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By adult child

Disclosed balance after: 1,000

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

SEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 1

SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By adult child

Disclosed balance after: 1,000

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.